Anavex Life Sciences Corp. (NASDAQ:AVXL) marched up 21.05% compared to a 52-week low price of $3.01. The shares were last seen trading 14.47% higher, taking the closing price at $3.64 on 12/21/2017. At recent session, the prices were hovering between $3.19 and $3.71. This company shares are 312.09% off its target price of $15 and the current market capitalization stands at $156.45M. The recent change has given its price a -7.87% deficit over SMA 50 and -45.18% deficit over its 52-week high. The stock witnessed -7.85% declines, -11.86% declines and -36.14% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AVXL’s volatility during a week at 7.01% and during a month it has been found around 6.27%.Anavex Life Sciences Corp. (AVXL) Top Holders
Institutional investors currently hold around $32 million or 22.9% in AVXL stock. Look at its top three institutional owners. Park West Asset Management Llc owns $9.14 million in Anavex Life Sciences Corp., which represents roughly 5.84% of the company’s market cap and approximately 28.56% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 1,791,639 shares of the stock are valued at $5.7 million. The third largest holder is Vanguard Group Inc, which currently holds $5.27 million worth of this stock and that ownership represents nearly 3.37% of its market capitalization.
At the end of 09/30/2017 reporting period, 28 institutional holders increased their position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by some 455,771 shares, 19 decreased positions by 712,581 and 20 held positions by 8,868,927. That puts total institutional holdings at 10,037,279 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 129,748 shares while 5 institutional investors sold out their entire positions totaling 54,867 shares.Anavex Life Sciences Corp. (NASDAQ:AVXL) Insider Trades
Multiple company employees have indulged in significant insider trading. Anavex Life Sciences Corp. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Missling Christopher U has acquired 375 shares of Anavex Life Sciences Corp. (AVXL) in trading session dated Oct. 25, 2017. These shares are worth $1,646 and were traded at $4.39 each. The SEC filing shows that Missling Christopher U performed a purchase of 375 shares. The President and CEO added these shares by way of transaction on Oct. 24, 2017. The company’s shares were assimilated at $4.92 per share worth to an investment of some $1,845 on account of Missling Christopher U.
President and CEO, Missling Christopher U, purchased 375 common shares of Anavex Life Sciences Corp. (AVXL) in the open market. In a transaction dated Oct. 19, 2017, the shares were bought at an average price of $4.49, giving away a sum of $1,684. After this purchase, 1,011,500 common shares of AVXL are directly owned by the insider, with total stake valued at $3,681,860.
In the transaction dated Oct. 17, 2017, the great number of shares acquired came courtesy the President and CEO; Missling Christopher U added a total of 375 shares at an average price of $4.27, amounting to approximately $1,601. The insider now directly owns 1,011,125 shares worth $3,680,495.Anavex Life Sciences Corp. (AVXL) Analyst Guide
Not many analysts have released their opinion on Anavex Life Sciences Corp. (NASDAQ:AVXL), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.